# Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

> **NCT03439657** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 913 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** HZ/su vaccine GSK1437173A
- **BIOLOGICAL:** Prevenar13

## Key facts

- **NCT ID:** NCT03439657
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-12
- **Primary completion:** 2019-05-06
- **Final completion:** 2020-03-03
- **Target enrollment:** 913 (ACTUAL)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03439657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03439657, "Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03439657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*